Natera, which sells non-invasive prenatal DNA tests, announced terms for its IPO on Monday.
The San Carlos, CA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Natera would command a fully diluted market value of $848 million.
Natera, which was founded in 2003 and booked $179 million in sales for the 12 months ended March 31, 2015, plans to list on the NASDAQ under the symbol NTRA. Morgan Stanley, Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of June 29, 2015.
